Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors.

Papadopoulos, Kyriakos P

Phase I safety, pharmacokinetic, and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid tumors. [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research May 2014 - 2445-56 p. digital

Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

1557-3265

10.1158/1078-0432.CCR-13-2403 doi


Administration, Oral
Adult
Aged
Aged, 80 and over
Antineoplastic Agents--pharmacology
Drug Monitoring
Female
Humans
Male
Maximum Tolerated Dose
Middle Aged
Neoplasm Staging
Neoplasms--drug therapy
Phosphoinositide-3 Kinase Inhibitors
Quinoxalines--pharmacology
Signal Transduction--drug effects
Sulfonamides--pharmacology
TOR Serine-Threonine Kinases--antagonists & inhibitors
Treatment Outcome
Young Adult